Patents Examined by Padmavathi Baskar
  • Patent number: 10881731
    Abstract: The present invention relates to methods for inducing an immune response, in particular methods for adjuvanting the immune response to an antigen comprising the separate administration of a saponin and a TLR4 agonist.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 5, 2021
    Inventors: Margherita Coccia, Arnauld Michel Didierlaurent
  • Patent number: 10875927
    Abstract: The present disclosure provides compositions and uses thereof for treating a disease or disorder associated with CD20 expression. Treatments of this disclosure include use of a host cell expressing a fusion protein, such as an anti-CD20 CAR, optionally in combination with a CD20-specific binding molecule, a chemotherapeutic, an inhibitor of an immunosuppression component, or combinations thereof.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: December 29, 2020
    Inventors: Oliver Press, Brian Till
  • Patent number: 10876103
    Abstract: Certain embodiments of the disclosure are directed to variant filamentous fungal cells, compositions thereof and methods thereof for increased production of one or more proteins of interest. More particularly, in certain embodiments, the disclosure is directed to variant filamentous fungal (host) cells derived from parental filamentous fungal cells, wherein the variant host cells comprise a genetic modification which enables the expression/production of a protein of interest (POI) in the absence of inducing substrate. In certain embodiments, a variant fungal host cell of the disclosure comprises a genetic modification which increases the expression of a variant activator of cellulase expression 3 (ace3) gene encoding an Ace3 protein referred to herein as Ace3-L.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: December 29, 2020
    Inventors: Michael Ward, Yun Luo, Felipe Oseas Bendezu, Mari Valkonen, Markku Saloheimo, Nina Aro, Tiina Pakula
  • Patent number: 10877037
    Abstract: Presented herein, in certain aspects, are compositions that comprise novel toxin proteins, the nucleic acids that encode them, and/or portions thereof, which toxins are expressed by fungi of the Mucorales order and are thought to contribute to the pathogenesis of Mucormycosis. Also presented herein, in certain aspects, are methods of detecting the presence or absence of novel fungal toxins and/or the nucleic acids that encode them in a sample, which methods can be used to identify the presence of Mucorales in a subject. Methods and/or compositions presented herein can be used to prevent and/or treat a Mucorales infection.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: December 29, 2020
    Inventors: Ashraf S. Ibrahim, Sameh Soliman, John Edwards, Jr.
  • Patent number: 10865429
    Abstract: An object of the invention is to improve the crystallization speed of a PHA copolymer which is to be slowly crystallized, and improve the melt workability and productivity. A microorganism is used which has genes encoding two or more different PHA synthases derived from the genus Aeromonas. The genes encoding the PHA synthases derived from the genus Aeromonas preferably include genes encoding at least two PHA synthases which are capable of synthesizing a copolymer PHA including, as monomer unit species, 3-hydroxybutyric acid and 3-hydroxyhexanoic acid, and which are different in substrate specificity toward 3-hydroxyhexanoic acid from each other. When this microorganism is cultured, a PHA mixture can be produced which includes three or more PHA species different in melting point from each other.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: December 15, 2020
    Inventors: Shingo Kobayashi, Hitoshi Sashiwa, Tetsuya Fujiki
  • Patent number: 10865246
    Abstract: The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: December 15, 2020
    Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido University
    Inventors: Satoru Konnai, Kazuhiko Ohashi, Shiro Murata, Tomohiro Okagawa, Asami Nishimori, Naoya Maekawa, Satoshi Takagi, Yumiko Kagawa, Yasuhiko Suzuki, Chie Nakajima
  • Patent number: 10858663
    Abstract: The current disclosure provides microorganisms, such as lactic acid bacteria (e.g., Lactococcus lactis) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a T1D-specific antigen (e.g., a proinsulin) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. The disclosure further provides compositions (e.g., pharmaceutical compositions) methods of using the microorganisms and compositions, e.g., for the treatment of type 1 diabetes (T1D), including those with residual beta-cell function, e.g., recent-onset T1D. The microorganism may be administered orally, delivers the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides, The methods of the present disclosure are particularly well suited for subjects possessing residual beta-cell function, e.g., for subjects with recent-onset T1D.
    Type: Grant
    Filed: September 2, 2017
    Date of Patent: December 8, 2020
    Inventors: Pieter Rottiers, Lothar Steidler
  • Patent number: 10858433
    Abstract: Provided is a monoclonal antibody against programmed death-1 (PD-1) or applications thereof, where the monoclonal antibody against PD-1 comprises a neonatal Fc Receptor (FcRn)-binding site having an amino acid sequence of SEQ ID NO: 5.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: December 8, 2020
    Assignees: Taizhou Hanzhong Biopharmaceutics, Inc., Akeso Biopharma, Inc.
    Inventors: Faming Zhang, Gan Xi, Ying Huang, Yu Xia, Baiyong Li, Zhongmin Maxwell Wang
  • Patent number: 10857227
    Abstract: The invention relates to the use of melanin, complexed with an antigen, as a immunostimulatory composition.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: December 8, 2020
    Inventors: Antoine Carpentier, Claire Banissi
  • Patent number: 10849968
    Abstract: The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: December 1, 2020
    Assignee: Evaxion Biotech ApS
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson
  • Patent number: 10842828
    Abstract: Described herein are methods of treating or preventing cancer in a subject comprising administering to the subject an effective amount of a bacteria comprising and expression vector encoding a di-adenylate cyclase enzyme.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: November 24, 2020
    Assignee: The Johns Hopkins University
    Inventors: William R. Bishai, Ruchi Jain Dey, Bappaditya Dey, Laurene Cheung
  • Patent number: 10835591
    Abstract: A complementary DNA (cDNA) with SEQ ID NO: 1 which encodes an immunogenic fragment of major outer sheath protein (Msp) of Treponema denticola.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: November 17, 2020
    Inventors: Mohsen Amin, Saba Hashemi
  • Patent number: 10836805
    Abstract: The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: November 17, 2020
    Inventors: Lai-Xi Wang, Wei Huang
  • Patent number: 10828356
    Abstract: Bacterial strains are provided having at least one of a reduced size, a sialic acid coat, inducibly altered surface antigens, and expression of PD-L1 or CTLA-4 antagonists and/or tryptophanase. The bacteria may have improved serum half-life, increased penetration into tumors, increased tumor targeting and increased antitumor activity. The bacteria are useful for delivery of therapeutic agents that treat of neoplastic diseases including solid tumors and lymphomas.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: November 10, 2020
    Inventor: David Gordon Bermudes
  • Patent number: 10828360
    Abstract: Disclosed are methods and kits of parts useful in inhibiting biofilm formation in vivo in subjects at risk of developing biofilms. These methods include inhibiting biofilm formation where the extracellular matrix in the biofilm includes poly-?-(1?6)glucosamine structures.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: November 10, 2020
    Assignee: OneBioPharma, Inc.
    Inventors: Michael Wyand, John Donnelly, Gerald F. Swiss
  • Patent number: 10829521
    Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: November 10, 2020
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark Edward Ruppen
  • Patent number: 10829562
    Abstract: The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: November 10, 2020
    Inventors: Karen Vanhoorelbeke, Shannen Deconinck, Hendrik Feys, An-Sofie Schelpe
  • Patent number: 10821169
    Abstract: Provided are compositions and methods for use in prophylaxis of puerperal metritis and improving reproductive function of ruminants. The methods and compositions are for subcutaneous administration and are provided as veterinary compositions and as articles of manufacture. The veterinary composition can contain whole cells selected from whole cells of Escherichia coli (E. coli), Trueperella pyogenes (T. pyogenes), Fusobacterium necrophorum (F. necrophorum) and combinations thereof; and/or proteins selected from F. necrophorum leukotoxin (LKT), E. coli type 1 fimbrial adhesin (FimH), T. pyogenes pyolysin (PLO), and all combinations of the whole cells and the proteins.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: November 3, 2020
    Assignee: Cornell University
    Inventors: Rodrigo Carvalho Bicalho, Robert Owen Gilbert, Vinicius Machado, Marcela Bicalho
  • Patent number: 10822417
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 3, 2020
    Assignee: Syntimmune, Inc.
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George E. Holgate, Timothy D. Jones, Arron R. Hearn
  • Patent number: 10813989
    Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: October 27, 2020
    Assignee: Pfizer Inc.
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Judith Absalon, Jose Miguel Aste-Amezaga, Johannes Frederik Beeslaar, David Cooper, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Isis Kanevsky, Lakshmi Khandke, Paul Liberator, John Lance Perez, Lynn Marie Phelan, Gary Warren Zlotnick